Open Access<p>Metastatic Hormone-sensitive Prostate Cancer: Current Perspective on the Evolving Therapeutic Landscape</p>
Author(s) -
Mary E. Hall,
Heather L. Huelster,
Amy N. Luckenbaugh,
Aaron A. Laviana,
Kirk A. Keegan,
Zachary Klaassen,
Kelvin A. Moses,
Christopher J.D. Wallis
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s228355
Subject(s) - enzalutamide , medicine , prostate cancer , abiraterone acetate , docetaxel , oncology , clinical trial , radiation therapy , metastasis , androgen deprivation therapy , disease , randomized controlled trial , chemotherapy , cancer , androgen receptor
The treatment landscape for patients with metastatic hormone-sensitive prostate cancer (mHSPC) has changed dramatically in the past five years, despite little change in the preceding 20 years. Such rapid change can make it difficult for clinicians to remain abreast of the current literature and synthesize the relevant data to inform evidence-based treatment decisions.